What We Are Funding
PPMD invests in research that will impact every boy touched by Duchenne, no matter his age, stage of progression, or mutation. Our Funding Portfolio highlights new treatments and therapies at various stages of development. Your support can turn their promise into success.
Current Projects Needing Funding
| YEAR |
TITLE |
RECIPIENT |
TYPE |
AMOUNT |
| 2012 |
Pilot Project to identify genetic modifiers of Duchenne muscular dystrophy |
Dr. Stanley Nelson, University of California, Los Angeles |
Research Grant |
$100,000 |
| 2012 |
Exons 45-55 skipping with a cocktail antisense oligo |
Dr. Toshifumi Yokota, University of Alberta |
Research Grant |
$50,000 |
| 2012 |
Long-term efficacy and side effect profile of compound A, a selective glucocorticoid receptor modulator in mdx mice |
Dr. Kanneboyina Nagaraju, Children’s Research Institute |
Research Grant |
$50,000 |
| 2012 |
Development of MEMRI as an outcome measure for pre-clinical studies in the mdx mouse |
Dr. Volker Straub, University of Newcastle Upon Tyne |
Research Grant |
$49,003 |
| 2014 |
Predicting the benefit vs the side effects of corticosteroids in Duchenne muscular dystrophy |
Dr. Robert Griggs, University of Rochester |
Research Grant |
$78,357 |
| 2012 |
Magnetic Resonance Imaging as a Biomarker in Muscular Dystrophy Supplement |
Dr. Kristen Vandenborne, University of Florida |
Research Grant |
$59,598 |
| 2012 |
Clinically Meaningful Outcomes for Duchenne Muscular Dystrophy Therapeutic Trials |
Dr. Erik Henricson, University of California, Davis |
Research Grant |
$175,000 |
| 2012 |
Early treatment with Aldosterone antagonism attenuates cardiomyopathy in Duchenne MD (Epleronone Trial) |
Dr. Kan Hor, Cincinnati Children's Hospital Medical Center |
Research Grant |
$84,092 |
Complete Funding Portfolio
In this section
Funding Portfolio
Programs & Priorities
Review Committees
|
